EPHA2 and melanoma: It remains unclear why higher frequencies of EphA2- and MAGE-6-specific CD4+ T cells were identified in female patients, although it has been previously reported that female melanoma patients have a generally better prognosis (i.e., longer survival) when compared to their male counterparts (30).